Related Experiment Video

Updated: Oct 26, 2025

Whole-body PET/MRI of Pediatric Patients: The Details That Matter
10:02

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Published on: December 19, 2017

14.8K

Toward integrated pediatric medicine: Key learnings from the pediatric integrative medicine trial

Maria Mayan1, Tatjana Alvadj2, Sarah Wildge1

  • 1Community University Partnership for the Study of Children, Youth and Families, Faculty of Extension, University of Alberta, Edmonton, Canada.

Explore (New York, N.Y.)
|July 26, 2021
PubMed

Insights

Integrating complementary therapies in pediatric hospitals is facilitated by open-mindedness, communication, and shared definitions of positive outcomes. This approach supports patient wellbeing by bridging conventional and complementary care practices.

Area of Science:

  • Integrative medicine
  • Pediatric healthcare
  • Complementary therapies

Background:

  • A qualitative descriptive study was conducted within a larger research project examining the implementation of a pediatric integrative medicine service.
  • The study focused on an acute care children's hospital in Canada, exploring the integration of complementary therapies into conventional practice.

Purpose of the Study:

  • To explore the facilitators for integrating complementary therapies into conventional pediatric hospital settings.
  • To understand the experiences of parents, healthcare providers, and complementary therapy providers regarding this integration.

Main Methods:

  • Qualitative descriptive study design.
  • Semi-structured one-on-one interviews conducted via telephone and in-person.
  • Interviews conducted with 50 key stakeholders, including parents, healthcare providers, and complementary therapy providers, between May 2014 and January 2016.

Main Results:

  • Facilitators for integration include stakeholders' open-mindedness and familiarity with diverse care practices.
  • Open communication, mutual respect for roles, and appreciation for complementary therapies are key facilitators.
  • Stakeholders' willingness to redefine 'positive outcomes' in hospital care also promotes integration.

Conclusions:

  • Creating an environment with a shared commitment to patient wellbeing can mediate barriers to integrating complementary therapies.
  • Successful integration hinges on fostering a collaborative atmosphere among all stakeholders involved in pediatric hospital care.
Abstract

Keywords:
Complementary therapiesIntegrative medicinePediatricsQualitative research

More Related Videos

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.0K
Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure15:18

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure

Published on: July 30, 2009

18.4K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
45
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
41
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
47
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
57
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.9K